Nombre: Marco Filice

Email: mfilice@ucm.es

Teléfono de contacto: +34913941750

Posición y cargo: Personal Docente Investigador - Programa '*Atracción de Talento Investigador*' de la Comunidad de Madrid (Modalidad 1)

Grupo de Investigación: Director del Grupo de '*NanoBioTecnología para Ciencias de la Vida*' (NBT4LS)

Docencia: Grado en Farmacia, Master de Investigación en Medicina Traslacional y Master en Biomateriales.

Área de Conocimiento: Química Física.

SCOPUS: 22937319100; **ORCID:** 0000-0001-8142-4566; **Researcher ID**: L-4848-2014.

Scopus Scholar

Biography: Dr Filice (Ph.D in Pharmaceutical Chemistry, Italy, 2007) spent the last 12 years as postdoc researcher in prestigious public and private research centers among Italy (University of Pavia-UNIPV), France (French National Centre for Scientific Research-CNRS), Brazil (São Paulo State University-UNESP) and Spain (Spanish National Research Council-CSIC and Spanish National Center for Cardiovascular Research-CNIC). In 2018, awarded with the 'Research Talent Attraction' Program, he joined to the Faculty of Pharmacy belonging to the Universidad Complutense de Madrid (UCM) where he founded the '*Nanobiotechnology for Life Sciences*' Group. His scientific production encompasses more than 68 publications in high impact factor ISI journals (Q1: >77%; H-Index 20), 5 book chapters or 1 complete book. He obtained and participated in more than 21 (13 as PI) R+D+i competitive national, international projects and research contracts with private companies. He belongs to the Biomedical Research Networking Centre for Respiratory Diseases (CIBERES) and he is Visiting Scientist in the Microscopy and Dynamic Imaging Unit of CNIC.

Research Line: The research activity of Dr. Filice is characterized by a strong multidisciplinary vision that ranges within Physical and Bioorganic Chemistry, Enzymology, Nanobiotechnology, Nanomedicine, Biosensing, Protein Chemistry or Biomedical Molecular Imaging. It is mainly focused on the fine design and controlled synthesis of novel multifunctional hybrid nanochimers as result of the combination of site-selective engineered biomolecules (e.g. peptides, proteins, antibodies, oligonucleotides) together with a wide set of customized functional nanomaterials. These nanochimers showed high usefulness as next-generation platforms in advanced biosensing and nanocatalysis as well as in nanomedicine as advanced theranostic (*thera*peutic+diag*nostic*) tools for biomedical applications in cancer, cardiovascular, respiratory and immune-based diseases.